Compare Dyne Therapeutics Inc. Common Stock (DYN) vs iShares MSCI Hong Kong ETF (EWH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs iShares MSCI Hong Kong ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while iShares MSCI Hong Kong ETF trades at $21.92 (market cap $1.19B). The key difference: Dyne Therapeutics Inc. Common Stock is far larger — about 2.4× iShares MSCI Hong Kong ETF's market cap, and iShares MSCI Hong Kong ETF is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and iShares MSCI Hong Kong ETF for 63 Days on average.
| DYN | EWH | |
|---|---|---|
Market Cap | $2.86B | $1.19B |
Volume | 3,341,579 | 2,118,222 |
Sector | Health | Broad Market / Factor |
52-Week High | $26.78 | $24.55 |
52-Week Low | $14.60 | $20.92 |
Typical Hold Time | 0 Days | 63 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
EWH, the iShares MSCI Hong Kong ETF, trades at $22.35 with a 1.78% daily gain amid bearish technical signals. The ETF faces headwinds from Hong Kong's Hang Seng Index decline, down over 11% from yearly highs due to Federal Reserve policy and US-Iran tensions. Technical indicators show mixed signals with bearish moving averages but neutral oscillators, while support and resistance cluster tightly around $22.
The outlook remains cautious given Hong Kong's market volatility and geopolitical risks. Investment opportunity exists for contrarian bets on Chinese tech recovery, but risks include sustained Fed tightening and regional tensions. Wall Street sentiment is divided, with some seeing value in oversold conditions while others warn of further downside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →
